StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

Equities research analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Saturday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities reissued a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $4.99 on Friday. The firm has a market capitalization of $102.64 million, a P/E ratio of -1.11 and a beta of 0.71. The business has a 50 day simple moving average of $4.48 and a 200 day simple moving average of $3.83. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $8.32.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.